
TY  - JOUR
TI  - Special Symposium, “Transplantation in the Hyperimmunized Patient”
JO  - Xenotransplantation
VL  - 16
IS  - 5
SN  - 0908-665X
UR  - https://doi.org/10.1111/j.1399-3089.2009.00539_3.x
DO  - doi:10.1111/j.1399-3089.2009.00539_3.x
SP  - 329
EP  - 389
PY  - 2009
ER  - 

TY  - JOUR
TI  - Poster Sessions Monday/Tuesday
JO  - Journal of Neurochemistry
JA  - J. Neurochem.
VL  - 142
IS  - S1
SN  - 0022-3042
UR  - https://doi.org/10.1111/jnc.14093
DO  - doi:10.1111/jnc.14093
SP  - 78
EP  - 164
PY  - 2017
ER  - 

TY  - JOUR
AU  - Padmanabhan, Anand
AU  - Connelly-Smith, Laura
AU  - Aqui, Nicole
AU  - Balogun, Rasheed A.
AU  - Klingel, Reinhard
AU  - Meyer, Erin
AU  - Pham, Huy P.
AU  - Schneiderman, Jennifer
AU  - Witt, Volker
AU  - Wu, Yanyun
AU  - Zantek, Nicole D.
AU  - Dunbar, Nancy M.
AU  - Schwartz, Guest Editor: Joseph
TI  - Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
JO  - Journal of Clinical Apheresis
JA  - J Clin Apher
VL  - 34
IS  - 3
SN  - 0733-2459
UR  - https://doi.org/10.1002/jca.21705
DO  - doi:10.1002/jca.21705
SP  - 171
EP  - 354
PY  - 2019
AB  - ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special Issue Writing Committee is charged with reviewing, updating and categorizing indications for the evidence-based use of therapeutic apheresis (TA) in human disease. Since the 2007 JCA Special Issue (Fourth Edition), the committee has incorporated systematic review and evidence-based approaches in the grading and categorization of apheresis indications. This Eighth Edition of the JCA Special Issue continues to maintain this methodology and rigor in order to make recommendations on the use of apheresis in a wide variety of diseases/conditions. The JCA Eighth Edition, like its predecessor, continues to apply the category and grading system definitions in fact sheets. The general layout and concept of a fact sheet that was introduced in the Fourth Edition, has largely been maintained in this edition. Each fact sheet succinctly summarizes the evidence for the use of TA in a specific disease entity or medical condition. The Eighth Edition comprises 84 fact sheets for relevant diseases and medical conditions, with 157 graded and categorized indications and/or TA modalities. The Eighth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.
ER  - 

C7  - pp. 167-196
TI  - Glia and Diseases of the Nervous System
SN  - 9780470015643
UR  - https://doi.org/10.1002/9780470517796.ch10
DO  - doi:10.1002/9780470517796.ch10
SP  - 167-196
KW  - Alexander's disease (AxD)
KW  - rapid demyelination
KW  - astrocytes and spreading depression incidence
KW  - global ischaemia and neuronal death
KW  - Charcot-Marie-Tooth disease (CMT)
KW  - Multiple sclerosis (MS) - inflammatory demyelinating disease
KW  - core–penumbra interactions
KW  - cytotoxic brain oedema
KW  - neurodegenerative diseases
KW  - neuropathic pain
PY  - 2019
AB  - Summary This chapter contains sections titled: Alexander's disease Spreading depression Stroke and ischaemia Cytotoxic brain oedema Neurodegenerative diseases Neuropathic pain Demyelinating diseases Infectious diseases Peripheral neuropathies Psychiatric diseases Gliomas
ER  - 

TY  - JOUR
TI  - 2016 Inflammatory Neuropathy Consortium and ‘GBS 100’ Centenary Symposium and Ceilidh
JO  - Journal of the Peripheral Nervous System
JA  - J Peripher Nerv Syst
VL  - 21
IS  - 3
SN  - 9780470015643
UR  - https://doi.org/10.1111/jns.12179
DO  - doi:10.1111/jns.12179
SP  - 157
EP  - 228
PY  - 2016
ER  - 

TY  - JOUR
TI  - ePresentation
JO  - European Journal of Neurology
JA  - Eur J Neurol
VL  - 24
IS  - S1
SN  - 9780470015643
UR  - https://doi.org/10.1111/ene.13368
DO  - doi:10.1111/ene.13368
SP  - 445
EP  - 678
PY  - 2017
ER  - 

TY  - JOUR
TI  - Abstract Supplement 2018 ACR/ARHP Annual Meeting
JO  - Arthritis & Rheumatology
JA  - Arthritis Rheumatol
VL  - 70
IS  - S9
SN  - 9780470015643
UR  - https://doi.org/10.1002/art.40700
DO  - doi:10.1002/art.40700
SP  - 1
EP  - 3584
PY  - 2018
AB  - Abstract For a searchable version of these abstracts, please visit www.acrabstracts.org.
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Acta Anaesthesiologica Scandinavica
VL  - 35
IS  - s96
SN  - 9780470015643
UR  - https://doi.org/10.1111/j.1399-6576.1991.tb03411.x
DO  - doi:10.1111/j.1399-6576.1991.tb03411.x
SP  - 7
EP  - 227
PY  - 1991
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - European Journal of Heart Failure
JA  - Eur J Heart Fail
VL  - 20
IS  - S1
SN  - 9780470015643
UR  - https://doi.org/10.1002/ejhf.1197
DO  - doi:10.1002/ejhf.1197
SP  - 5
EP  - 638
PY  - 2018
ER  - 

TY  - JOUR
TI  - Program: First joint meeting of the American society for bone and mineral research and the international conferences on calcium regulating hormones
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 4
IS  - S1
SN  - 9780470015643
UR  - https://doi.org/10.1002/jbmr.5650040702
DO  - doi:10.1002/jbmr.5650040702
SP  - 1
EP  - 419
PY  - 1989
ER  - 

TY  - JOUR
TI  - Abstracts of papers presented at the Second Meeting of the European Haematology Association, Paris, France, 29 May-1 June 1996
JO  - British Journal of Haematology
VL  - 93
IS  - S2
SN  - 9780470015643
UR  - https://doi.org/10.1111/j.1365-2141.1996.tb08988.x
DO  - doi:10.1111/j.1365-2141.1996.tb08988.x
SP  - 1
EP  - 372
PY  - 1996
ER  - 

TY  - JOUR
TI  - Oral Presentations
JO  - Mycoses
JA  - Mycoses
VL  - 57
IS  - s2
SN  - 9780470015643
UR  - https://doi.org/10.1111/myc.12216
DO  - doi:10.1111/myc.12216
SP  - 15
EP  - 30
PY  - 2014
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Experimental Dermatology
JA  - Exp Dermatol
VL  - 26
IS  - S1
SN  - 9780470015643
UR  - https://doi.org/10.1111/exd.13298
DO  - doi:10.1111/exd.13298
SP  - 3
EP  - 38
PY  - 2017
ER  - 

TY  - JOUR
TI  - Abstract of Paper to be Presented at American Association of Blood Banks: 42 Annual Meeting October 21–26, 1989
JO  - Transfusion
VL  - 29
IS  - S7
SN  - 9780470015643
UR  - https://doi.org/10.1046/j.1537-2995.29.7s.1.x
DO  - doi:10.1046/j.1537-2995.29.7s.1.x
SP  - 4S
EP  - 88S
PY  - 1989
ER  - 

TY  - JOUR
AU  - Isbister, James P.
TI  - Hazards of Homologous Blood Transfusion
JO  - Transfusion Alternatives in Transfusion Medicine
VL  - 4
IS  - 4
SN  - 9780470015643
UR  - https://doi.org/10.1111/j.1778-428X.2002.tb00074.x
DO  - doi:10.1111/j.1778-428X.2002.tb00074.x
SP  - 129
EP  - 137
KW  - Blood transfusion
KW  - Risks
KW  - Transfusion-related infections
KW  - Storage lesions
KW  - Immunologically mediated reactions
KW  - Prestorage leukoreduction
PY  - 2002
AB  - SUMMARY In the current era of evidence-based medical practice, clinicians should ensure they have a good understanding of the potential benefits of and indications for potentially dangerous homologous blood component therapy. More attention is now being given to assessing the appropriateness of homologous transfusion therapy, with efforts to establish better evidence of improvements in patient outcomes. Such an approach allows for a more logical and realistic analysis of the risk/benefit equation in clinical management. In this summary of our current knowledge of the potential hazards of homologous blood transfusion, transfusion-transmitted infections are not addressed in detail, as most of the major problems relating to HIV and viral hepatitis have been solved and good reviews are available in the literature. In this review of the potential hazards of homologous blood transfusion, the focus is on many of the other areas of concern regarding the risk/benefit equation for homologous transfusion. Transfusion-related immunosuppression, the clinical significance of storage lesions, the potential adverse effects of leukocytes, error minimization, transfusion-related lung injury and less well-known immunological incompatibilities are addressed.
ER  - 

TY  - JOUR
TI  - SUBJECT INDEX
JO  - Annals of the New York Academy of Sciences
JA  - Annals of the New York Academy of Sciences
VL  - 711
IS  - 1
SN  - 9780470015643
UR  - https://doi.org/10.1111/j.1749-6632.1994.tb00016.x
DO  - doi:10.1111/j.1749-6632.1994.tb00016.x
SP  - 201
EP  - 597
PY  - 1994
ER  - 

TY  - JOUR
C7  - e13383
TI  - Oral Sessions
JO  - Acta Physiologica
JA  - Acta Physiol
VL  - 227
IS  - S719
SN  - 9780470015643
UR  - https://doi.org/10.1111/apha.13383
DO  - doi:10.1111/apha.13383
SP  - e13383
PY  - 2019
ER  - 

AU  - Marshall, John C.
AU  - Malam, Zeenat
AU  - Jia, Songhui
C7  - pp. 53-72
TI  - Modulating Neutrophil Apoptosis
SN  - 9780470027981
UR  - https://doi.org/10.1002/9780470059593.ch5
DO  - doi:10.1002/9780470059593.ch5
SP  - 53-72
KW  - modulating neutrophil-apoptosis
KW  - Polymorphonuclear neutrophils (PMNs)
KW  - bystander injury to host tissues in neutrophil activation
KW  - cellular mechanisms inhibiting apoptosis
KW  - pre-colony B cell enhancing factor (PBEF)
PY  - 2019
AB  - Summary Polymorphonuclear neutrophils are short-lived phagocytic cells that serve as cardinal early cellular effectors of innate immunity. Both oxidative and non-oxidative mechanisms contribute to microbial killing by the neutrophil. Neutrophil defence mechanisms are potent but non-specific, with the result that inadvertent injury to host tissues commonly accompanies the activation of a neutrophil-mediated response; this bystander injury has been implicated in the tissue injury of sepsis. The capacity for neutrophils to cause injury to host tissues is attenuated by the relatively short in vivo lifespan of the neutrophil, a consequence of a constitutively expressed program of apoptosis. That program can be inhibited, and neutrophil survival prolonged, through the interaction of the neutrophil with a variety of mediators of both microbial and host origin. These, in turn, inhibit apoptosis by increasing the expression of anti-apoptotic genes within the neutrophil: interleukin (IL)1? and a novel cytokine-like molecule pre-B cell colonyenhancing factor (PBEF) are central to this inhibitory influence. Conversely, the phagocytosis of a micro-organism activates the apoptotic program, and so contributes to the resolution of acute inflammation. A complex series of interactions between the neutrophil and microorganisms or their products regulates the duration and intensity of an inflammatory response, and so provides an attractive target for therapeutic manipulation.
ER  - 

TY  - JOUR
TI  - 2018 Annual Meeting of the American Society for Bone and Mineral Research Palais des congrès de Montréal in Montréal, Quebéc, Canada September 28 – October 1, 2018
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 33
IS  - S1
SN  - 9780470027981
UR  - https://doi.org/10.1002/jbmr.3621
DO  - doi:10.1002/jbmr.3621
SP  - S1
EP  - S464
PY  - 2018
ER  - 

TY  - JOUR
TI  - Abstracts of the 21st Annual Meeting of the European Society for Clinical Investigation, March 21 -24, Copenhagen-Elsinore, Denmark
JO  - European Journal of Clinical Investigation
VL  - 17
IS  - 2
SN  - 9780470027981
UR  - https://doi.org/10.1111/j.1365-2362.1987.tb02041.x
DO  - doi:10.1111/j.1365-2362.1987.tb02041.x
SP  - A3
EP  - A71
PY  - 1987
ER  - 
